Abstract
ObjectiveIntrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver cancer with limited therapeutic options. KRAS mutations are among the most abundant genetic alterations in iCCA associated with poor clinical...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have